Hemophilia A:

Our ELISA ZYMUTEST™ Anti-VIII IgG Mono Strip detects factor VIII antibodies of the IgG isotype, which can be developed by patients with acquired hemophilia A. Its features at a glance:

• Standardized quantitative assay
• High precision within and between laboratories
• Easy procedure: Usually one single dilution per patient is sufficient
• No falsification by factor VIII (no heat inactivation required)
• No falsification by Emicizumab, lupus anticoagulants, DOACs
• Applicable also for type II inhibitors with non-linear inactivation kinetics
• Prognostic value for patients with acquired hemophilia A ¹
• Detection of non-inhibitory antibodies: 
  • Can often be detected earlier than inhibitors ² ³
  • Risk factor for the development of inhibitors ² ⁴
  • Shorten the half-life of factor VIII products ⁵

Download IFU

References:

¹ Werwitzke S et al. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. J Thromb Haemost. 2016 May;14(5):940-7. doi: 10.1111/jth.13304. Epub 2016 Apr 22. PMID: 26988717.

² Boylan B et al. Hemophilia Inhibitor Research Study Investigators; Hemophilia Inhibitor Research Study Investigators. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768. Epub 2014 Dec 11. PMID: 25354263; PMCID: PMC4383171.

³ Hofbauer CJ et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood. 2015 Feb 12;125(7):1180-8. doi: 10.1182/blood-2014-09-598268. Epub 2014 Dec 16. PMID: 25515962.

⁴ Cannavò A et al. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood. 2017 Mar 9;129(10):1245-1250. doi: 10.1182/blood-2016-06-720086. Epub 2016 Dec 29. Erratum in: Blood. 2017 Jul 13;130(2):232. PMID: 28034891.

⁵ Hofbauer CJ et al. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. Blood. 2016 Jul 14;128(2):293-6. doi: 10.1182/blood-2015-10-675512. Epub 2016 May 23. PMID: 27216215.